Ease-of-use, preference, confidence, and satisfaction with Revolizer(®), a novel dry powder inhaler, in an Indian population.
BACKGROUND
While prescribing an inhaler device, it is important to take into account the usability, preference, confidence, and satisfaction of the patients.


OBJECTIVE
The present study assessed these parameters with Revolizer(®), a novel dry powder inhaler (DPI), in patients with obstructive airway diseases and in device-naïve healthy participants.


METHODS
In this open-label, prospective, multicentre study with 100 participants [n = 50 healthy participants, n = 45 mild asthma patients, and n = 5 mild chronic obstructive pulmonary disease (COPD) patients], all participants were instructed and trained on the use of Revolizer and then the participants subsequently demonstrated the inhalation technique at two visits.


METHODS
The average time required to execute three correct consecutive attempts and the number of errors (including critical errors) were recorded. Participants were asked about the ease of use, preference, confidence, and satisfaction by means of a questionnaire at each visit.


RESULTS
The average time required by the participants to achieve three correct consecutive attempts at visit 1 was 3.75 ± 2.10 min, which significantly reduced at visit 2 (3.07 ± 1.32 min, P < 0.01). The number of errors decreased from visit 1 to visit 2. More than 85% participants found the Revolizer easy to use, and it was preferred by more than 75% participants. Revolizer scored high on the confidence and satisfaction of all participants at both visits.


CONCLUSIONS
Revolizer is an easy-to-use and a preferred device in patients with mild asthma and COPD, as well as in healthy participants with no previous experience of using inhalation devices. The participants felt confident and satisfied using the Revolizer.
Department of Chest Medicine, Bhatia Hospital and Bombay Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
Sujeet K
SK
Rajan
Chief Medical Officer, Department of Medical Services, Cipla Limited, Mumbai, Maharashtra, India.
Jaideep A
JA
Gogtay
Asthma; Revolizer; chronic obstructive pulmonary disease; dry powder inhalers; patient preference